Study on Cycloset™ for Type 2 Diabetes Treatment
Author Information
Author(s): Richard E Scranton, J Michael Gaziano, Dean Rutty, Michael Ezrokhi, Anthony Cincotta
Primary Institution: Veroscience LLC, Harvard Medical School
Hypothesis
The rate of all-cause serious adverse events after one year of usual diabetes therapy plus Cycloset™ is not greater than that for usual diabetes therapy plus placebo.
Conclusion
The study aims to evaluate the safety and efficacy of Cycloset™ in individuals with type 2 diabetes.
Supporting Evidence
- Cycloset™ has been shown to reduce insulin resistance and improve glycemic control in clinical trials.
- The study includes a large sample size of 3,095 participants.
- Participants are randomized in a 2:1 ratio to receive either Cycloset™ or placebo.
Takeaway
This study is testing a new diabetes medication called Cycloset™ to see if it is safe and helps people with diabetes better than a sugar pill.
Methodology
A double-blind, multi-center, placebo-controlled trial with a 2:1 randomization ratio over one year.
Potential Biases
Potential conflicts of interest due to authors' affiliations with the developing company.
Limitations
The study may not account for all potential confounding factors affecting diabetes management.
Participant Demographics
Individuals aged 30-80 with type 2 diabetes and HbA1c ≤ 10%.
Statistical Information
Confidence Interval
1.5
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website